Cigna Group 8-K filings
NYSE
The Cigna Group has entered into new revolving credit agreements totaling $6.5 billion, replacing its existing facilities.
NYSE
8-K: Cigna Group Raises Long-Term EPS Growth Target, Unveils New Healthcare Solutions at Investor Day
The Cigna Group announced an increased long-term adjusted EPS growth target and new healthcare solutions at its 2024 Investor Day.
NYSE
The Cigna Group has entered into agreements to repurchase $3.2 billion of its common stock as part of its existing share repurchase program.
NYSE
8-K: Cigna Group Issues $4.5 Billion in Senior Notes to Fund Debt Repurchase and General Corporate Needs
The Cigna Group has successfully issued $4.5 billion in senior notes across four tranches to fund tender offers, debt repayment, and general corporate purposes.
NYSE
The Cigna Group has successfully priced a $4.5 billion offering of senior notes to fund tender offers for existing debt, repay maturing notes, and for general corporate purposes.
NYSE
The Cigna Group announced strong fourth quarter and full year 2023 results, increased its 2024 adjusted EPS outlook, and raised its quarterly dividend by 14%.
NYSE
Cigna has agreed to sell its Medicare Advantage, Supplemental Benefits, Part D, and CareAllies businesses to Health Care Service Corporation for approximately $3.7 billion, expecting to close the deal in the first quarter of 2025.
NYSE
Mary Agoglia Hoeltzel, Senior Vice President and Chief Accounting Officer of The Cigna Group, has announced her retirement effective July 1, 2024.
NYSE
The Cigna Group has announced organizational changes, including expanded roles for Brian C. Evanko and Eric P. Palmer, effective February 5, 2024.